MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer
ConclusionThe activity and safety of first-line FOLFIRI/aflibercept merit further evaluation in randomized studies.Clinicaltrials.gov registration numberNCT02624726.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Hypertension | Proteinuria | Study | Toxicology